Morepen Laboratories (NSE:MOREPENLAB) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
74 GF Score
Price ₹53.16
GF Value ₹49.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Morepen Laboratories Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Morepen Laboratories's operating assets for the quarter that ended in Mar. 2026 was ₹18,284 Mil. Morepen Laboratories's operating liabilities for the quarter that ended in Mar. 2026 was ₹4,812 Mil. Morepen Laboratories's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Morepen Laboratories's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Morepen Laboratories Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Scaled Net Operating Assets Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.71 0.77 0.92 0.76

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:MOREPENLAB vs ZTS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Scaled Net Operating Assets falls into.


NSE:MOREPENLAB
74GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Morepen Laboratories's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(18284.452-4811.751)/17780.993
=0.76

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=19361.201 - 1076.749
=18284.452

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6890.303 - 1378.614 - 699.938
=4811.751

Morepen Laboratories's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(18284.452-4811.751)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=19361.201 - 1076.749
=18284.452

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6890.303 - 1378.614 - 699.938
=4811.751

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹53.16 is trading 6.7% above its estimated GF Value™ of ₹49.82. GuruFocus considers Morepen Laboratories to be Fairly Valued.

Key valuation signals for NSE:MOREPENLAB:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹49.82 vs. price of ₹53.16 (6.7% above fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score

Get the complete analysis for NSE:MOREPENLAB

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹53.16
Price
₹49.82
GF Value